A Review of the Use of Biological Agents in Human Immunodeficiency Virus Positive Patients With Rheumatological Diseases

After approval, initial biologics etanercept, infliximab, and adalimumab became useful in the therapeutic armamentarium to treat rheumatoid arthritis (RA) patients who had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). However, all phase-III clinical trials submitted to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Attallah, Marline A, Jarrin Jara, Maria Daniela, Gautam, Avneesh S, Peesapati, Venkata Sri Ramani, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667623/
https://www.ncbi.nlm.nih.gov/pubmed/33209528
http://dx.doi.org/10.7759/cureus.10970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667623/
https://www.ncbi.nlm.nih.gov/pubmed/33209528
http://dx.doi.org/10.7759/cureus.10970

Ejemplares similares